Group 1 - The core viewpoint of the news is that China COSCO Shipping International reported a 2% increase in revenue to HKD 3.706 billion for the year ending December 31, 2025, primarily driven by higher income from the paint and ship trading agency segments [1] - The profit attributable to equity holders rose by 9% to HKD 771 million, mainly due to increased revenue, share of profits from a joint venture, and net foreign exchange gains [1] - Basic and diluted earnings per share increased by 9% to HKD 0.526 [1] - The board proposed a final dividend of HKD 0.19 per share and an additional special dividend of HKD 0.10 per share [1] Group 2 - Following the earnings announcement, China COSCO Shipping International's stock fell over 5%, trading at HKD 6.53 with a transaction volume of HKD 27.0928 million [2]

云游控股 分时图 日K线 周K线 月K线 0.81 -0.01 -1.22% 4.88% 3.66% 1.22% 0.00% 1.22% 3.66% 4.88% 0.78 0.79 0.81 0.82 0.83 0.85 0.86 09:30 10:30 12:00/13:00 14:00 16:10 0 1167 2333 3500 云游控股(00484)发布公告，自2026年3月25日起，卢杨先生(卢先生)已获委任为本公司执行董事及首席 投资官。 ...

联合集团 公告称，收入增加乃主要由于天安中国投资有限公司的上海天安1号二期(C区)已售住宅单位于2025年年 初交付予客户后所确认的收入所致。公司股东应占年度溢利为22.24亿港元，而2024年的亏损为7.77亿港 元。集团财务表现的显著改善乃主要由于以下各项的增加：新鸿基有限公司应占溢利;天安应占溢利， 而非2024年的应占亏损;及应占公司上市联营公司亚太资源有限公司业绩的应占溢利，而非2024年应占 业绩取得的应占亏损。 分时图 日K线 周K线 月K线 2.65 -0.12 -4.33% 7.58% 5.05% 2.53% 0.00% 2.53% 5.05% 7.58% 2.56 2.63 2.70 2.77 2.84 2.91 2.98 09:30 10:30 12:00/13:00 14:00 16:10 0 3万 6万 10万 联合集团(00373)发布2025年度的经审核业绩，该集团取得收入150.68亿港元，同比增长98.67%;股东应 占溢利22.24亿港元，去年同期亏损7.77亿港元;每股基本盈利0.63港元。拟宣派截至2025年12月31日止 年度的中期股息(代替末期股息)每股10港仙。 ...

Group 1 - Cathay Pacific Airways (00293) announced the cancellation of 643 million treasury shares on March 26, 2026 [2] - The company's stock performance shows a slight decline of 0.12% to 12.31, with a year-to-date change of -0.97% [1] - The trading volume reached 136,000 shares during the day [1] Group 2 - The stock price has shown fluctuations throughout the day, with a high of 12.58 and a low of 12.28 [1] - The company is actively managing its share structure by reducing the number of outstanding shares [2] - The announcement of share cancellation may impact investor sentiment positively by potentially increasing earnings per share [2]

Group 1 - The company reported a profit attributable to owners of $122.8 million for the year ending December 31, 2025, representing a 6.0% increase from $115.9 million for the year ending December 31, 2024, driven by growth in earnings before interest, taxes, depreciation, and amortization from development properties [1] - The overall profit attributable to owners was $112.3 million, a decrease of 30.4% compared to $161.4 million for the year ending December 31, 2024, reflecting a reduction of $56 million in non-operating items [1] Group 2 - Shangri-La Asia (00069) reported a total revenue of $2.234 billion for the year ending December 31, 2025, an increase of 2.2% year-on-year [2] - The company’s profit attributable to owners was $112 million, a year-on-year decrease of 30.42% [2] - Basic earnings per share were 3.16 cents, and the company proposed a final dividend of 10 Hong Kong cents per share [2]

Core Viewpoint - Alibaba Health has partnered with Novartis to establish a digital chronic disease management collaboration in the field of Chronic Spontaneous Urticaria (CSU), leveraging Alibaba Health's digital platform to provide integrated services for patients, including disease education, medication guidance, and comprehensive health management [3][6]. Group 1: Partnership Details - The collaboration focuses on Novartis' oral targeted drug, Remibrutinib (brand name: Ruipuduo), which aims to address the clinical challenges faced by CSU patients [3][6]. - The partnership will utilize Alibaba Health's "full-cycle chronic disease management system" to create an "out-of-hospital second clinic" for patients [7]. Group 2: Market Context - CSU affects over 10 million patients in China, characterized by recurrent hives and severe itching, often leading to anxiety and social withdrawal [6]. - Current first-line treatments, such as antihistamines, are ineffective for over 50% of patients, highlighting the need for new therapeutic options like Remibrutinib [6]. Group 3: Treatment Efficacy - Remibrutinib is a highly selective BTK inhibitor that provides a new treatment option by blocking the release of signals that cause itching and hives, offering rapid onset and sustained efficacy [6]. - Clinical trials indicate that patients using Remibrutinib can see significant symptom improvement within one week, with sustained benefits over a 52-week treatment period [6].

Core Viewpoint - Geely Automobile announced the issuance of 1.782 million ordinary shares due to employee stock options exercised under a plan adopted on April 28, 2023, and an additional 46,000 shares for related entity participants under the same plan [1] Group 1 - Geely Automobile will issue a total of 1.782 million shares on March 26, 2026, as a result of employees exercising stock options [1] - An additional 46,000 shares will be issued on the same date for related entity participants exercising stock options [1]

中国海外发展(00688)发布公告，中海企业发展集团有限公司2025年度第一期中期票据(品种一)将于2026 年4月14日付息，本期债券简称："25中海企业MTN001A";发行总额:5亿元;本计息期债券利率:1.90%。 分时图 日K线 周K线 月K线 11.88 -0.12 -1.00% 1.42% 0.92% 0.50% 0.00% 0.50% 0.92% 1.42% 11.83 11.89 11.94 12.00 12.06 12.11 12.17 09:30 10:30 12:00/13:00 14:00 16:10 0 104万 207万 311万 中国海外发展 ...

Core Insights - The company reported a strong business development trajectory, achieving insurance service revenue of 570.72 billion yuan in 2025, a year-on-year increase of 6.1% [1] - The total assets of the group reached 2,027.59 billion yuan, reflecting a growth of 14.8% compared to the previous year [1] Financial Performance - The total operating revenue for the year was 669.25 billion yuan, representing a year-on-year increase of 7.56% [3] - The net profit attributable to shareholders was 46.21 billion yuan, up 9.62% year-on-year, with basic earnings per share of 1.04 yuan [3] - The proposed final dividend is 1.45 yuan per 10 shares [3] Insurance Business Development - In property insurance, the company maintained a market share of 33.16%, leading the industry [2] - The underwriting profit reached 12.54 billion yuan, a significant increase of 119.4% year-on-year, with a comprehensive cost ratio of 97.5%, down 1.3 percentage points [2] - In life insurance, the original premium income grew by 18.8%, with first-year premium income increasing by 32.4% [2] Investment Performance - The company achieved total investment income of 92.99 billion yuan, a year-on-year increase of 13.2%, with a stable total investment return rate of 5.6% [2] - The investment asset scale surpassed 1.90 trillion yuan, growing by 15.8% since the beginning of the year [1] Cash Flow and New Business - The net cash inflow from operating activities was 43.05 billion yuan, up 18.1% year-on-year [2] - New business value on a comparable basis increased by 64.5%, with a new business contract service margin of 17.38 billion yuan, up 22.8% [2]

Group 1 - The core viewpoint of the news is that Country Garden has issued a profit warning, expecting a profit between 1 billion to 2.2 billion for the fiscal year 2025, following a loss of 35.145 billion in the previous year [1] - The anticipated profit turnaround is primarily attributed to non-cash gains from debt restructuring, while excluding these gains, the company still faces losses due to industry pressures affecting gross margins and impairment provisions on certain assets and property projects [1] - Yang Huiyan emphasized that 2026 will be a critical year for the company to transition from "ensuring delivery" to normal operations, with the next 3 to 5 years being a significant period for growth [1] Group 2 - The company plans to focus on building core competitiveness, with a customer-oriented approach in product services, advancing the fourth generation of residential designs, and catering to diverse demographic needs such as aging populations and pet-friendly designs [1] - Country Garden aims to leverage its full industry chain advantages to integrate product design and property services, facilitating a second growth phase for the company [1]